The DOI matches its Crossref record.
Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia.
Open accessAbstract
The Philadelphia chromosome (Ph'), detected in virtually all cases of chronic myelogenous leukemia (CML), is formed by a reciprocal translocation between chromosome 9 and 22 that fuses Bcr-encoded sequences upstream of exon 2 of c-Abl.This oncogene produces a fusion protein, p210bcr-"b', in which the Ab1 tyrosine kinase activity is elevated.Using anti-phosphotyrosine immunoblotting, we have compared the pattern of phosphotyrosine-containing proteins from freshly prepared neutrophils of patients in the stable phase of CML to normal controls.The only consistent difference was the presence of a 39-kDa tyrosine-phosphorylated protein in 18 out of 18 neutrophil samples from CML patients that was not seen in normal controls.This same protein, as assessed by two-dimensional anti-phosphotyrosine immunoblotting, was also present in cell lines expressing p210b"""*', including K562 cells.Using K562 cells as a source of protein, the 39-kDa protein was purified and identified by microsequencing as Crkl, an SH2/SH3 adaptor protein related to the crk oncogene of the avian sarcoma virus, CT10.A direct interaction between Crkl and Ab1 has also been shown using a yeast two-hybrid screen.The p210bcr-"b' oncogene, present in virtually all cases of chronic myelogenous leukemia (CML),l is derived from a hybrid gene created by the Philadelphia chromosomal translocation (1-4).This hybrid gene has elevated protein tyrosine kinase activity and has been shown to cause a CML-like syndrome in mice (5, 6) and to transform immature hematopoietic cells in CA 36167 and 34183 (to J. D. G.) and CA 01422 (to B. J. D.).The costs
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Self-citationTracking cancer drugs in living cells by thermal profiling of the proteome
Savitski, M. M., Reinhard, F. B. M., Franken, H., Werner, T., Savitski, M. F., Eberhard, D., Molina, D. M., Jafari, R., Dovega, R. B., Klaeger, S., et al. (2014) · Science · doi:10.1126/science.1255784 · Cited by 1,187
Druker, B. J., & Lydon, N. B. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9083 · Cited by 707
Self-citationTranslation of the Philadelphia chromosome into therapy for CML
Druker, B. J. (2008) · Blood · doi:10.1182/blood-2008-07-077958 · Cited by 668
Self-citation
Metadata
- Authors
- Oda, T., Heaney, C., Hagopian, J. R., Okuda, K., Griffin, J. D., & Druker, B. J.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1994-09
- Volume
- 269
- Issue
- 37
- Pages
- 22925-22928
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W1484834653
- Cited by
- 272
- References
- 0
- FWCI
- 5.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. https://app.cochat.ai/papers/10.1016/s0021-9258(17)31596-x
- The paper
- Oda, T., Heaney, C., Hagopian, J. R., Okuda, K., Griffin, J. D., & Druker, B. J. (1994). Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. Journal of Biological Chemistry. https://doi.org/10.1016/s0021-9258(17)31596-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.